NCT05045963

Impact of Aminoglycosides in Hypotensive Septic Oncology Patients

Evaluating the Impact of Aminoglycosides in Hypotensive Septic Oncology Patients

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 232 (actual)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates the impact of aminoglycosides in hypotensive septic oncologic patients. In the oncologic patient population, sepsis is a major health concern due to high mortality rates and healthcare costs. Prior research shows aminoglycosides antibiotics are frequently used to treat sepsis, but their clinical impact in hypotensive oncology patients upon the progression of sepsis is not known.

Detailed description

PRIMARY OBJECTIVE: I. To assess the impact of beta-lactam (BL) + aminoglycoside (AG) combination therapy in hypotensive septic oncology patients. OUTLINE: Patients' medical charts are reviewed retrospectively.

Conditions

• Hematopoietic and Lymphoid Cell Neoplasm
• Malignant Solid Neoplasm
• Septicemia

Interventions

Type	Name	Description
OTHER	Electronic Health Record Review	Medical record reviewed

Timeline

• Start date: 2021-01-04
• Primary completion: 2026-02-13
• Completion: 2026-02-13
• First posted: 2021-09-16
• Last updated: 2026-02-20

Locations

1 site across 1 country: United States